Dasatinib salts

The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Virag Attila, Tothne Lauritz Maria Dr, Dr. Marvanyos Ede Laszlo, Varga Zoltan, Dr. Pongo Laszlo, Dr. Lukacs Gyula, Dr. Dancso Andras, Dr. Volk Balazs, dr. Gregor Tamas, Peregi Balazs
Format: Patent
Sprache:eng ; hun
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Virag Attila
Tothne Lauritz Maria Dr
Dr. Marvanyos Ede Laszlo
Varga Zoltan
Dr. Pongo Laszlo
Dr. Lukacs Gyula
Dr. Dancso Andras
Dr. Volk Balazs
dr. Gregor Tamas
Peregi Balazs
description The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HU231013B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HU231013B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HU231013B13</originalsourceid><addsrcrecordid>eNrjZOB3SSxOLMnMy0xSKE7MKSnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxHqFGxoYGhsZOhsaEVQAACM8d-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Dasatinib salts</title><source>esp@cenet</source><creator>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</creator><creatorcontrib>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</creatorcontrib><description>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</description><language>eng ; hun</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20191128&amp;DB=EPODOC&amp;CC=HU&amp;NR=231013B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25571,76555</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20191128&amp;DB=EPODOC&amp;CC=HU&amp;NR=231013B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Virag Attila</creatorcontrib><creatorcontrib>Tothne Lauritz Maria Dr</creatorcontrib><creatorcontrib>Dr. Marvanyos Ede Laszlo</creatorcontrib><creatorcontrib>Varga Zoltan</creatorcontrib><creatorcontrib>Dr. Pongo Laszlo</creatorcontrib><creatorcontrib>Dr. Lukacs Gyula</creatorcontrib><creatorcontrib>Dr. Dancso Andras</creatorcontrib><creatorcontrib>Dr. Volk Balazs</creatorcontrib><creatorcontrib>dr. Gregor Tamas</creatorcontrib><creatorcontrib>Peregi Balazs</creatorcontrib><title>Dasatinib salts</title><description>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOB3SSxOLMnMy0xSKE7MKSnmYWBNS8wpTuWF0twM8m6uIc4euqkF-fGpxQWJyal5qSXxHqFGxoYGhsZOhsaEVQAACM8d-A</recordid><startdate>20191128</startdate><enddate>20191128</enddate><creator>Virag Attila</creator><creator>Tothne Lauritz Maria Dr</creator><creator>Dr. Marvanyos Ede Laszlo</creator><creator>Varga Zoltan</creator><creator>Dr. Pongo Laszlo</creator><creator>Dr. Lukacs Gyula</creator><creator>Dr. Dancso Andras</creator><creator>Dr. Volk Balazs</creator><creator>dr. Gregor Tamas</creator><creator>Peregi Balazs</creator><scope>EVB</scope></search><sort><creationdate>20191128</creationdate><title>Dasatinib salts</title><author>Virag Attila ; Tothne Lauritz Maria Dr ; Dr. Marvanyos Ede Laszlo ; Varga Zoltan ; Dr. Pongo Laszlo ; Dr. Lukacs Gyula ; Dr. Dancso Andras ; Dr. Volk Balazs ; dr. Gregor Tamas ; Peregi Balazs</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HU231013B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; hun</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Virag Attila</creatorcontrib><creatorcontrib>Tothne Lauritz Maria Dr</creatorcontrib><creatorcontrib>Dr. Marvanyos Ede Laszlo</creatorcontrib><creatorcontrib>Varga Zoltan</creatorcontrib><creatorcontrib>Dr. Pongo Laszlo</creatorcontrib><creatorcontrib>Dr. Lukacs Gyula</creatorcontrib><creatorcontrib>Dr. Dancso Andras</creatorcontrib><creatorcontrib>Dr. Volk Balazs</creatorcontrib><creatorcontrib>dr. Gregor Tamas</creatorcontrib><creatorcontrib>Peregi Balazs</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Virag Attila</au><au>Tothne Lauritz Maria Dr</au><au>Dr. Marvanyos Ede Laszlo</au><au>Varga Zoltan</au><au>Dr. Pongo Laszlo</au><au>Dr. Lukacs Gyula</au><au>Dr. Dancso Andras</au><au>Dr. Volk Balazs</au><au>dr. Gregor Tamas</au><au>Peregi Balazs</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Dasatinib salts</title><date>2019-11-28</date><risdate>2019</risdate><abstract>The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; hun
recordid cdi_epo_espacenet_HU231013B1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Dasatinib salts
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T12%3A35%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Virag%20Attila&rft.date=2019-11-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHU231013B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true